Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SpheChon
- Development stage
- Unknown
- Lead developer
- ReLive Biotechnologies
- Modality
- Hematopoietic Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies, Autologous CAR-T → CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Mesenchymal Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies, Patient-derived iPSCs → iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intraarticular
01
Overview
SpheChon is an autologous cell therapy product developed by ReLive Biotechnologies for the repair of symptomatic articular cartilage defects in the knee. The therapy consists of patient-derived chondrocytes that are cultured and formed into three-dimensional spheroid structures. These spheroids are implanted into the defect site (specifically ICRS grade III or IV defects of the femoral condyle or patella) to promote the regeneration of hyaline-like cartilage tissue. In December 2023, SpheChon received New Drug Application (NDA) approval from Singapore's Health Sciences Authority (HSA), making it the first approved cell therapy for cartilage repair in Singapore. It is indicated for use in adults and adolescents with closed epiphyseal growth plates for defect sizes ranging from 1 cm² to 10 cm².
- Brand names
- SpheChon
- Other names
- chondrocyte spheroids
Beyond the preview
Go deeper on SpheChon.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SpheChon.